PCSK9, which reduces LDL receptor recycling, is increased. E3-ubiquitin ligase inducible degrader of the LDL receptor has a similar function, but its role in familial hypercholesterolemia (FH ...

High cholesterol levels lead to plaque formation in arteries that restrict blood and oxygen flow. Familial ...

PCSK9 mutations can either activate or inactivate its action, raising or lowering plasma LDL levels and coronary heart ...

third-generation PCSK9 inhibitor today announced the publication of Phase 3 LIBerate-HoFH study of Lerodalcibep in a globally diverse homozygous familial hypercholesterolemia (HoFH) population was ...

Dr Jay Edelberg, Head of the PCSK9 Development and Launch Unit at Sanofi discusses the ongoing clinical trial assessing PCSK9 inhibitors for use in patients with high cholesterol, in our ...

single-course solution for tackling high cholesterol levels. “Statins and PCSK9 inhibitors are phenomenal meds and we have so much evidence that they can reduce risk, but we see a huge gap in ...

Familial hypercholesterolemia (FH ... novel treatments like proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These new therapies can help achieve LDL-C goals more effectively ...

An antibody, already approved as a treatment for high cholesterol, prevents the PCSK9 protein from removing the brake, and “we see that we get a reduction in breast cancer metastasis ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...

Under the PCSK9 program collaboration agreement ... of VERVE-201 administration in adult patients with refractory hypercholesterolemia (RH) who require additional lowering of LDL-C despite ...